A focused business portfolio across sirolimus-eluting and covered stents, semi-compliant and non-compliant PTCA balloons, and 0.014-inch guidewire platforms.
Sirolimus-eluting cobalt-chromium stents are reviewed by strut architecture, polymer strategy, drug dose and release profile, radial support, side-branch access, crossing profile and length matrix. Representative documented systems cover 2.25–5.00 mm diameters and include extended lengths.
Single-layer ePTFE-covered cobalt-chromium platforms are assessed by coverage integrity, hybrid-cell geometry, flarable ends, diameter/length matrix, delivery length and nominal/rated burst pressure.
Semi-compliant balloons support lesion preparation and controlled sizing. Non-compliant high-pressure balloons support precise post-dilatation and resistant-lesion strategies. Conical geometries may address tapered or bifurcated anatomy.
Wire portfolios are differentiated by core design, distal coating, radiopaque coil, tip shape and tip load. Representative reviewed lengths are 185 and 300 cm, with straight and J-tip variants.
Figures summarize selected manufacturer-controlled ranges reviewed by Azucena; they do not substitute product-specific IFUs.
| Technology | Representative diameter | Length / catheter | Compatibility | Commercial review focus |
|---|---|---|---|---|
| Drug-eluting coronary stent | 2.25–5.00 mm | 10–48 mm by family | 0.014-inch wire · 5F/6F by model | Polymer, drug release, strut and size matrix |
| Covered coronary stent | 2.25–6.00 mm | 10–38 mm · 142 cm delivery | 0.014-inch wire | Coverage, crossing profile, pressure rating |
| Semi-compliant PTCA | Model dependent | 15–40 mm reviewed · 140 cm catheter | 0.014-inch wire · minimum 5F | Compliance, lesion role, conical options |
| Non-compliant PTCA | 1.50–5.00 mm reviewed | 140 cm catheter | 0.014-inch wire · minimum 5F | RBP, growth curve, post-dilatation role |
| PTCA guidewire | 0.014 inch | 185 / 300 cm | Straight or J-tip | Core, coating, coil and tip load |
All model codes, exact dimensions, pressure limits, indications, contraindications and warnings must be verified against the current controlled manufacturer documentation before procurement or use.
A coronary portfolio is commercially viable only when its evidence, documentation, production and replenishment model fit the target market.
Published evidence, test reports, usability, biocompatibility, sterilization and shelf-life documentation.
Validated manufacturing, size availability, lead time, order structure and change-control discipline.
Registration status, labelling language, local requirements, channel capability and responsible training support.
Start with the target market, clinical role and documentation status.